Read the Beforeitsnews.com story here. Advertise at Before It's News here.
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views
Now:
Last hour:
Last 24 hours:
Total:

AIM ImmunoTech advances bid to study Ampligen as therapy for Post-COVID-19 Cognitive Dysfunction

% of readers think this story is Fact. Add your two cents.


AIM ImmunoTech Inc has progressed a step further in its bid to get Ampligen into a clinical trial to test it as an infusion therapy for Post-COVID-19 Cognitive Dysfunction (PCCD) – a new and serious coronavirus-induced disease for which there is currently no treatment.

The FDA has deemed a meeting request sufficient for transfer now to the regulator’s Division of Neurology by the FDA’s Covid scientific technical triage team.

The planned Phase 2 randomized, double blind, placebo controlled, multicenter study will be managed by Amarex Clinical Research and is designed to evaluate the efficacy and safety of Ampligen in patients experiencing PCCD.

READ: AIM ImmunoTech offers a status update on its pending Phase 2a Human Challenge Trial using its flagship drug Ampligen

“We are pleased with this next step - the referral to the FDA’s Division of Neurology - as our focus is on the brain-related symptoms of Long COVID,” said AIM CEO Thomas K. Equels in a statement.

The trial will see 80 patients randomized 1:1 to receive twice-weekly infusions of Ampligen or placebo for 12 weeks.

Dr. Kazem Kazempour, Amarex Clinical Research CEO, added: “FDA alignment with the strategy illustrates a positive step forward in finding a treatment for PCCD.

“Moreover, it is both exciting and gratifying to be working on this product for AIM. This is a new and serious COVID-induced disease indication for which there is currently no treatment.”

AIM ImmunoTech Inc is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.

Contact the author at [email protected]

Story by ProactiveInvestors



Source: https://www.proactiveinvestors.com/companies/news/960893/aim-immunotech-advances-bid-to-study-ampligen-as-therapy-for-post-covid-19-cognitive-dysfunction-960893.html


Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Please Help Support BeforeitsNews by trying our Natural Health Products below!


Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST

Order by Phone at 888-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST

Order by Phone at 888-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST


Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!

HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation

Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.

MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser!  Cleans out toxic buildup with oxygen! 
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover -  Reduces Smart Meter radiation by 96%!  (See Video)

Immusist Beverage Concentrate - Proprietary blend, formulated to reduce inflammation while hydrating and oxygenating the cells.

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

MOST RECENT
Load more ...

SignUp

Login

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.